A trial reports that an experimental daily pill for advanced pancreatic cancer nearly doubles survival time compared with standard chemotherapy given by infusion. Multiple outlets describe the treatment as aimed at patients with an advanced and aggressive form of pancreatic cancer. According to the coverage, participants taking the pill live for close to twice as long as those receiving chemotherapy during the study period. The reports also note that the new treatment has a different side-effect profile, with fewer side effects than chemotherapy in the trial results. Several articles characterize the findings as a significant breakthrough, using terms such as “transformative,” while others focus on the clinical comparison and outcomes. The sources are aligned that the evidence comes from a trial, that it involves oral (pill) treatment rather than infusion chemotherapy, and that the primary reported benefit is longer survival. The coverage does not provide consistent figures on exact survival durations or detailed trial methodology in the excerpts, but the overall message is that the pill improves survival and is better tolerated than chemotherapy for this patient group.